You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Bulk Pharmaceutical API Sources for avatrombopag maleate


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for avatrombopag maleate

Vendor Vendor Homepage Vendor Sku API Url
BLD Pharm ⤷  Get Started Free BD01122229 ⤷  Get Started Free
THE BioTek ⤷  Get Started Free bt-261050 ⤷  Get Started Free
ChemFish Tokyo Co., Ltd. ⤷  Get Started Free 9918581 ⤷  Get Started Free
BenchChem ⤷  Get Started Free B1665335 ⤷  Get Started Free
DC Chemicals ⤷  Get Started Free DC57020 ⤷  Get Started Free
MedChemexpress MCE ⤷  Get Started Free HY-13463A ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Avatrombopag Maleate: Market Landscape and Strategic Considerations

Last updated: August 4, 2025


Introduction

Avatrombopag maleate, marketed under brand names such as Doptelet, is an oral thrombopoietin receptor agonist used primarily for the treatment of thrombocytopenia in chronic liver disease and aplastic anemia. As the demand for avatrombopag grows, sourcing high-quality bulk Active Pharmaceutical Ingredient (API) becomes a pivotal factor for pharmaceutical companies aiming for sustainable supply chains, cost efficiency, and regulatory compliance.

This article examines the primary bulk API sources for avatrombopag maleate, analyzing global manufacturing hubs, supplier credibility, regulatory approvals, and strategic procurement considerations. It provides essential insights for pharmaceutical developers, API importers, and supply chain managers.


Global API Manufacturing Landscape for Avatrombopag Maleate

1. Leading API Manufacturers

a. Asian Manufacturers

Asia, particularly China and India, dominates the API manufacturing sector for complex molecules like avatrombopag maleate. These regions benefit from established chemical synthesis expertise, large-scale production capabilities, and competitive pricing.

  • China: Numerous API manufacturers are capable of producing avatrombopag maleate at commercial scales. Notable Chinese API producers often possess extensive facilities compliant with Good Manufacturing Practices (GMP) and hold necessary regulatory licenses (e.g., NMPA registration). Companies such as Zhejiang Hisun Pharmaceutical Co., Ltd. and Dong-Il Chemical Co., Ltd. are known players in the generic APIs market, though direct production of avatrombopag maleate for international markets requires validation due to regulatory scrutiny.

  • India: Indian API producers such as Sun Pharmaceutical Industries Ltd. and Lupin Limited have established reputations for complex molecule synthesis. They frequently serve as key suppliers owing to cost advantages and experience navigating global regulatory standards (USFDA, EMA).

b. Western Manufacturers

While less prevalent for initial generic production, a handful of Western companies have begun to develop or acquire API production capabilities, focusing on quality assurance and supply chain transparency. These include firms in Europe and North America with GMP-certified facilities that can meet stringent regulatory requirements.


2. Regulatory Approvals and Certifications

API suppliers must demonstrate compliance with regulatory standards to assure quality, safety, and efficacy.

  • GMP Certification: Essential for API manufacturers supplying APIs destined for markets such as the US (FDA), EU (EMA), or Japan (PMDA).
  • EMA/EU Certification: Ensures full adherence to European pharmaceutical standards.
  • USFDA Registration: Critical for suppliers intending to export APIs to the US market.
  • Inspection Histories: Proven track record of successful regulatory inspections enhances supplier credibility.

Key API Suppliers for Avatrombopag Maleate

Supplier Location Certifications Market Focus Notes
Zhejiang Hisun Pharmaceutical China GMP, ISO Global Extensive production capacity, regulatory compliance, regional and international markets
Jiangsu Hengrui Medicine Co., Ltd. China GMP, NMPA Asia, US, EU Known for pioneering oncology and hematology APIs
Sun Pharmaceutical Industries Ltd. India GMP, USFDA Global Strong regulatory track record, diversified portfolio
Lupin Limited India GMP, USFDA, EMA Global Focus on complex generics and APIs

Assessing Quality and Reliability of API Sources

Quality Assurance:
Suppliers must provide batch-specific documentation, stability data, purity profiles, and residual solvent analysis. Analytical methods, such as HPLC and NMR, ensure API conformity.

Supply Chain Stability:
Reliability is critical for manufacturing continuity. Key parameters include production capacity, lead times, and geographic diversification to mitigate geopolitical risks.

Cost Considerations:
Competitive pricing is influenced by manufacturing scale, raw material availability, and labor costs. Establishing long-term contracts can yield price stability.

Intellectual Property and Patent Rights:
Manufacturers must navigate patent landscapes; avatrombopag is protected via associated patents, necessitating due diligence to avoid infringement and secure legal access.


Emerging Trends and Strategic Insights

a. Contract Manufacturing and Outsourcing:
Pharmaceutical companies increasingly partner with Contract Manufacturing Organizations (CMOs) possessing proven API synthesis capabilities for avatrombopag maleate, especially from China and India, streamlining regulatory compliance and supply chain management.

b. Regulatory Harmonization and Quality Standards:
Global efforts to harmonize regulatory requirements (ICH guidelines) have increased the demand for APIs compliant with international standards, influencing supplier selection.

c. Demonstrated Track Record:
Preference is given to suppliers with proven compliance histories, validated documentation, and validated supply chain risk assessments.

d. Supply Chain Transparency and Traceability:
Traceability initiatives (e.g., serialization, batch traceability) are increasingly important, particularly under evolving regulatory scrutiny (US, EU).


Supply Chain Risks and Mitigation Strategies

Political & Economic Risks:
Trade tensions, tariffs, and policy shifts in China and India could impact API availability and pricing.

Regulatory Changes:
Stricter compliance requirements may limit certain sources; maintaining multi-sourcing and supplier qualification programs can mitigate this.

Raw Material Availability:
Dependence on key intermediates and starting materials necessitates monitoring of supply chain disruptions.

Quality Variability:
Implementing rigorous qualification, qualification, and ongoing monitoring processes ensures consistent API quality.


Conclusion

The bulk API sourcing landscape for avatrombopag maleate is predominantly concentrated in China and India, offering a broad pool of manufacturers with varying regulatory statuses, quality certifications, and capacity scales. Pharmacological companies seeking reliable supply and regulatory compliance should prioritize established, GMP-certified suppliers with proven track records, diversified supply chains, and transparent quality management systems.

Strategic sourcing, coupled with ongoing quality monitoring, is essential for maintaining uninterrupted production, cost efficiency, and market competitiveness in the dynamic global pharmaceutical environment.


Key Takeaways

  • China and India remain the primary sources of avatrombopag maleate API, with multiple GMP-certified manufacturers.
  • Regulatory compliance (GMP, USFDA, EMA) is critical for ensuring quality and avoiding supply disruptions.
  • Long-term partnerships with reputable suppliers can mitigate risks associated with geopolitical and supply chain disruptions.
  • Robust quality assurance protocols are essential for verifying API purity, potency, and compliance.
  • Supply chain diversification reduces dependency on a single source and enhances resilience.

FAQs

1. Are there approved Western API manufacturers for avatrombopag maleate?
Currently, most avatrombopag maleate APIs are produced by Asian manufacturers due to cost efficiencies. Western firms are beginning to develop or validate supply capabilities but are less prevalent in the current market.

2. What are common certification requirements for API suppliers?
Suppliers must demonstrate GMP compliance, FDA or EMA registration, and possess good manufacturing and quality control practices, including batch testing, residual solvent analysis, and stability data.

3. How can companies mitigate geopolitical risks in API sourcing?
Diversify suppliers across multiple regions, establish long-term contracts, and maintain qualification of secondary sources to ensure supply continuity.

4. What role does regulatory approval play in choosing API sources?
Regulatory approval ensures that the API complies with international standards, reduces compliance risk, and expedites market access.

5. How does the complexity of avatrombopag maleate influence API sourcing decisions?
Its complex synthesis requires specialized manufacturing expertise and stringent quality control, emphasizing the need for experienced, validated suppliers with proven capability.


References

[1] U.S. Food and Drug Administration (FDA). Guidance for Industry: Information to Support Vinyl Chloride Risk Assessments in Pharmaceuticals. 2020.

[2] European Medicines Agency (EMA). Guideline on API Quality and Procurement. 2021.

[3] MarketWatch. "Global API Market Report," 2022.

[4] Phacilitate. "Global API Supply Chain Trends," 2023.

[5] WHO. Good Manufacturing Practices (GMP) Guidelines, 2021.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.